Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
Clinical trial NCT04776252 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04776252
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-15
- Primary completion
- 2029-05-29
- Enrollment
- 2000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.